Incyte Corporation (INCY) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$97.47
Price Target
$109.50
Target Range
$90.00 — $135.00
Analyst Rating
Buy
Forward P/E13.0x
Trailing P/E15.2x
Forward PEG—
Implied Growth+8.1%
Median Target$108.50
Analyst Spread41.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$90
-7.7%
Consensus
$110
+12.3%
Bull Case
$135
+38.5%
INCY Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Incyte Corporation (INCY) has a Wall Street consensus price target of $109.50, based on estimates from 44 covering analysts. With the stock currently trading at $97.47, this represents a potential upside of +12.3%. The company has a market capitalization of $19.47B.
Analyst price targets range from a low of $90.00 to a high of $135.00, representing a 41% spread in expectations. The median target of $108.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,19 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, INCY trades at a trailing P/E of 15.2x and forward P/E of 13.0x. Analysts expect EPS to grow +8.1% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+20.7%
Avg Forward P/E17.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ALKSAlkermes plc | $6.1B | $36.25 | $44.00 | +21.4% | Buy | — | 28 |
 JAZZJazz Pharmaceuticals plc | $13.3B | $212.26 | $216.14 | +1.8% | Buy | 8.8x | 48 |
 EXELExelixis, Inc. | $11.3B | $44.42 | $45.71 | +2.9% | Buy | 13.4x | 32 |
 HALOHalozyme Therapeutics, Inc. | $7.8B | $65.87 | $78.33 | +18.9% | Buy | 8.2x | 27 |
 IONSIonis Pharmaceuticals, Inc. | $12.4B | $75.25 | $107.27 | +42.6% | Buy | — | 32 |
 ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.35 | $34.78 | +55.6% | Buy | 50.4x | 37 |
 BMYBristol-Myers Squibb Company | $116.2B | $56.92 | $62.00 | +8.9% | Hold | 9.0x | 41 |
 ABBVAbbVie Inc. | $364.6B | $206.15 | $256.64 | +24.5% | Buy | 14.5x | 41 |
 PFEPfizer Inc. | $150.4B | $26.44 | $27.27 | +3.1% | Hold | 8.9x | 39 |
 LLYEli Lilly and Company | $933.7B | $988.19 | $1258.47 | +27.4% | Buy | 28.6x | 45 |
Upside Potential Comparison
ACADIONSLLYABBVALKSHALOBMYPFEFull INCY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See INCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INCY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINCY — Frequently Asked Questions
Quick answers to the most common questions about buying INCY stock.
What is the INCY stock price target for 2026?
Incyte Corporation (INCY) has a consensus 12-month price target of $109.5, implying 12.3% upside from $97.47. The 44 analysts covering INCY see moderate appreciation potential.
Is INCY a buy, sell, or hold?
INCY has a consensus rating of "Buy" based on 44 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $109.5 implies 12.3% upside from current levels.
Is INCY stock overvalued or undervalued?
With a forward P/E of 13.0224x, INCY trades at a relatively low valuation. The consensus target of $109.5 implies 12.3% appreciation, suggesting meaningful undervaluation.
How high can INCY stock go?
The most bullish Wall Street analyst has a price target of $135 for INCY, while the most conservative target is $90. The consensus of $109.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover INCY stock?
INCY is heavily covered by Wall Street, with 44 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 23 have Buy ratings, 19 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the INCY stock forecast?
The 12-month INCY stock forecast based on 44 Wall Street analysts shows a consensus price target of $109.5, with estimates ranging from $90 (bear case) to $135 (bull case). The median consensus rating is "Buy".
What is INCY's forward P/E ratio?
INCY trades at a forward P/E ratio of 13.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy INCY stock?
Wall Street analysts are optimistic on INCY, with a "Buy" consensus rating and $109.5 price target (12.3% upside). 23 of 44 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do INCY price targets vary so much?
INCY analyst price targets range from $90 to $135, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $109.5 consensus represents the middle ground.